FrancophonIA/ELRC3.0 huggingface dataset:
English: The most common adverse reactions were bleeding complications (see section 4.4).
Danish: De mest almindelige bivirkninger var blødningskomplikationer (se pkt.
English: PHARMACEUTICAL FORM AND CONTENTS Solution for injection, 2 pre-filled syringes with an automatic safety system Solution for injection, 7 pre-filled syringes with an automatic safety system Solution for injection, 10 pre-filled syringes with an automatic safety system Solution for injection, 20 pre-filled syringes with an automatic safety system Solution for injection, 2 pre-filled syringes with a manual safety system Solution for injection, 10 pre-filled syringes with a manual safety system Solution for injection, 20 pre-filled syringes with a manual safety system
Danish: Injektionsvæske, opløsning, 2 fyldte injektionssprøjter med automatisk sikkerhedssystem Injektionsvæske, opløsning, 7 fyldte injektionssprøjter med automatisk sikkerhedssystem Injektionsvæske, opløsning, 10 fyldte injektionssprøjter med automatisk sikkerhedssystem Injektionsvæske, opløsning, 20 fyldte injektionssprøjter med automatisk sikkerhedssystem
English: In STEMI patients undergoing primary PCI, the use of fondaparinux prior to and during PCI is not recommended.
Danish: STEMI-patienter, som gennemgår primær PCI, bør ikke behandles med fondaparinux før og under PCI-proceduren.
English: Following once daily dosing, steady state of plasma levels is obtained after 3 to 4 days with a 1.3-fold increase in Cmax and AUC.
Danish: Ved en daglig dosis opnås steady state-plasmakoncentration efter 3-4 dage med en 1,3 gange øget Cmax og AUC.
English: Patients were randomised to receive fondaparinux 2.5 mg once daily or placebo for 45 days in addition to elastic stockings, analgesic and/or topical NSAIDS anti-inflammatory drugs.
Danish: Patienterne blev randomiseret til fondaparinux 2,5 mg en gang daglig eller placebo i 45 dage samtidig med støttestrømper, analgetika og/eller topikal NSAID.
English: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and genotoxicity.
Danish: Der er ikke observeret nogen speciel fare for mennesker i ikke kliniske data baseret på traditionelle studier af sikkerhedsfarmakologi og genotoksicitet.
English: Dispose of it as your doctor or pharmacist has instructed.
Danish: Smid den ud, som anvist af din læge eller apoteket.
English: At the 10 mg dose used in interaction studies, fondaparinux did not significantly influence the anticoagulation activity (INR) of warfarin.
Danish: Ved den dosis på 10 mg, som blev anvendt i interaktionsstudier, påvirkede fondaparinux ikke warfarins antikoagulerende virkning (INR) signifikant.
English: Patients with superficial-vein thrombosis
Danish: Patienter med superficiel venetrombose
English: Fondaparinux 2.5 mg once daily started 6-8 hours postoperatively was compared with enoxaparin 40 mg once daily started 12 hours before surgery, or 30 mg twice daily started 12-24 hours after surgery.
Danish: Fondaparinux 2,5 mg en gang daglig med første administration 6-8 timer postoperativt blev sammenlignet med enoxaparin 40 mg en gang daglig med første administration 12 timer før kirurgi, eller 30 mg to gange daglig med første administration 12-24 timer efter kirurgi.
English: Major bleeding during treatment occurred in 1 (0.1%) fondaparinux patient and in 1 (0.1%) placebo patient.
Danish: Alvorlige blødninger under behandlingen opstod hos 1 (0,1 %) fondaparinuxpatient og hos 1 (0,1 %) placebo-patient.
English: • leg pain or stomach pain
Danish: • smerter i benene eller mavesmerter
English: Clinical experience is limited in patients with body weight <50 kg. Fondaparinux should be used with caution at a daily dose of 5 mg in this population (see sections 4.2 and 5.2).
Danish: Der er begrænsede kliniske erfaringer hos patienter, der vejer <50 kg. Fondaparinux bør anvendes med forsigtighed til denne patientgruppe og i en døgndosis på 5 mg (se pkt.
English: Treatment with fondaparinux was demonstrated to be non-inferior to unfractionated heparin (VTE rates 3.8% and 5.0%, respectively).
Danish: Studiet viste, at behandling med fondaparinux ikke er ufraktioneret heparin underlegen (forekomst af VTE henholdsvis 3,8 % og 5,0 %).
English: The primary adjudicated endpoint was a composite of death and recurrent MI (re-MI) within 30 days of randomisation.
Danish: Det primære sammensatte endepunkt var død og reinfarkt (re-MI) senest 30 dage efter randomisering.
English: Fondaparinux does not bind to platelet factor 4 and does not cross-react with sera from patients with Heparin Induced Thrombocytopenia (HIT) type II.
Danish: Fondaparinux binder ikke til trombocytfaktor 4, og giver normalt ikke krydsreaktion med sera fra patienter med heparininduceret trombocytopeni type II (HIT II).
English: Fondaparinux doses above the recommended regimen may lead to an increased risk of bleeding.
Danish: Fondaparinux doser ud over det anbefalede niveau kan øge blødningstendensen.
English: • Treatment of UA/NSTEMI and STEMI - For the treatment of UA/NSTEMI and STEMI, there are limited clinical data available on the use of fondaparinux 2.5mg once daily in patients with creatinine clearance between 20 and 30 ml/min.
Danish: • Behandling af UA/NSTEMI og STEMI - Der er kun begrænsede kliniske data vedrørende behandling af UA/NSTEMI og STEMI med 2,5 mg fondaparinux daglig til patienter med kreatininclearance mellem 20 og 30 ml/min.
English: Fondaparinux is contra-indicated in severe renal impairment (creatinine clearance <30 ml/min) and should be used with caution in patients with moderate renal impairment (creatinine clearance 30-50 ml/min).
Danish: Fondaparinux er kontraindiceret ved svært nedsat nyrefunktion (kreatininclearance <30 ml/min) og bør anvendes med forsigtighed til patienter med moderat nedsat nyrefunktion (kreatininclearance 3050 ml/min).
English: • The other ingredient(s) are sodium chloride, water for injections, and hydrochloric acid and/or sodium hydroxide to adjust the pH (see section 2).
Danish: • Øvrige indholdsstoffer: natriumchlorid, vand til injektionsvæsker og saltsyre og/eller natriumhydroxid til pH-justering (se punkt 2).
English: Minor gastrointestinal bleeding was reported in another patient on day 5 of therapy which resulted in temporary discontinuation of fondaparinux.
Danish: På dag 5 blev der hos en anden patient observeret mindre gastrointestinal blødning, hvilket resulterede i midlertidigt ophør med fondaparinux.
English: Following once daily subcutaneous dosing, steady state of plasma levels is obtained after 3 to 4 days with a 1.3-fold increase in Cmax and AUC.
Danish: Ved en daglig subkutan dosis opnås steady state-plasmakoncentration efter 3-4 dage med en 1,3 gange øget Cmax og AUC.
English: • internal bleeding in the brain or abdomen
Danish: • indre blødning i hjernen eller maven
English: Treatment of unstable angina (UA) or non-ST segment elevation myocardial infarction (NSTEMI) in patients who underwent subsequent PCI with adjunctive UFH
Danish: Behandling af ustabil angina (UA) eller non-ST-elevationsmyokardieinfarkt (NSTEMI) hos patienter, som efterfølgende har gennemgået PCI med adjuverende UFH
English: Treatment of ST segment elevation myocardial infarction (STEMI) OASIS 6 was a double blind, randomised study assessing the safety and efficacy of fondaparinux 2.5 mg once daily, versus usual care (placebo (47%) or UFH (53%) in approximately 12,000 patients with STEMI.
Danish: OASIS 6 var en dobbeltblindet, randomiseret undersøgelse til vurdering af sikkerhed og Virkning ved subkutan administration af fondaparinux 2,5 mg en gang daglig versus sædvanlig behandling (placebo (47 %) eller UFH (53 %)) blandt ca. 12.000 patienter med STEMI.
English: Instruction on self-administration by subcutaneous injection is included in the Package Leaflet.
Danish: Instruktion i subkutan selvinjektion findes beskrevet i indlægssedlen.
English: The duration of treatment should not exceed that evaluated during clinical trial (mean 7 days) (see sections 4.2, 4.3 and 5.2).
Danish: Behandlingens varighed bør ikke overskride det tidsrum, der blev evalueret under kliniske forsøg (gennemsnit 7 dage) (se pkt.
English: This stops a clotting factor Xa (“ten-A”) from working in the blood, and so prevents unwanted blood clots (thromboses) from forming in the blood vessels.
Danish: Dette forhindrer koagulationsfaktor Xa (”ti-A”) i at fungere i blodet, og forebygger derved dannelsen af uønskede blodpropper (tromboser) i blodkarrene.
English: The majority of endpoint events were diagnosed by a prescheduled venography and consisted mainly of distal DVT, but the incidence of proximal DVT was also significantly reduced.
Danish: De fleste endepunkt-hændelser blev diagnosticeret ved planlagt flebografi og bestod især af distal DVT.
English: Do not inject a double dose to make up for a forgotten dose.
Danish: • Tag den manglende dosis, så snart du kommer i tanke om den. Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis.
English: For additional instructions for use and handling and disposal see section 6.6.
Danish: For yderligere instruktioner om regler for destruktion og anden håndtering, se pkt.
English: Over 8,000 patients (hip fracture - 1,711, hip replacement - 5,829, major knee surgery - 1,367) were studied in controlled Phase II and III clinical studies.
Danish: Over 8.000 patienter (hoftefraktur: n=1711; hoftealloplastik: n=5829; større knæoperationer: n=1367) blev inkluderet i kontrollerede kliniske fase II- og III-studier.
English: Fondaparinux 5 mg (body weight < 50 kg), 7.5 mg (body weight ≥ 50kg, ≤ 100 kg) or 10 mg (body weight >100 kg) SC once daily was compared to unfractionated heparin IV bolus (5,000 IU) followed by a continuous IV infusion adjusted to maintain 1.5-2.5 times aPTT control value.
Danish: Fondaparinux 5 mg (legemsvægt <50 kg), 7,5 mg (legemsvægt ≥50kg, ≤100 kg) eller 10 mg (legemsvægt >100 kg) administreret subkutant en gang daglig blev sammenlignet med ufraktioneret heparin som intravenøs bolusinjektion (5.000 IE) efterfulgt af en kontinuerlig intravenøs infusion justeret, så der opretholdtes en kontrolværdi på 1,5-2,5 gange aPTT.
English: Arixtra is available in pack sizes of 2, 7, 10 and 20 pre-filled syringes.
Danish: Arixtra fås i pakninger med 2, 7, 10 og 20 fyldte injektionssprøjter.
English: Spinal / Epidural anaesthesia
Danish: Spinal-/epiduralanæstesi
English: Rare: bilirubinaemia
Danish: Sjælden: bilirubinæmi
English: Treatment of unstable angina/non- ST segment elevation myocardial infarction (UA/NSTEMI) The recommended dose of fondaparinux is 2.5 mg once daily, administered by subcutaneous injection.
Danish: Behandling af ustabil angina/non-ST segment elevations myokardieinfarkt (UA/NSTEMI) Den anbefalede fondaparinuxdosis er 2,5 mg daglig, administreret som subkutan injektion.
English: In the Phase III study in STEMI patients, the most commonly reported non-bleeding adverse events (reported in at least 1% of subjects on fondaparinux) were atrial fibrillation, pyrexia, chest pain, headache, ventricular tachycardia, vomiting, and hypotension.
Danish: I fase III-undersøgelsen med STEMI-patienter var de hyppigst rapporterede bivirkninger udover blødning (der blev rapporteret hos mindst 1 % af alle patienter, som fik fondaparinux), atrieflimren, feber, brystsmerter, hovedpine, ventrikulær takykardi, opkastning og hypotension.
English: Fondaparinux may be restarted at least 6 hours post-operatively provided haemostasis has been achieved.
Danish: Behandlingen med fondaparinux kan genoptages mindst 6 timer efter operationen, hvis hæmostase er opnået.
English: Picture F
Danish: Figur F
English: In patients >75 years undergoing orthopaedic surgery, the estimated plasma clearance was 1.2 to 1.4 times lower than in patients <65 years.
Danish: Hos patienter over 75 år, der gennemgik ortopædisk operation, blev plasmaclearance vurderet til 1,2 til 1,4 gange lavere end hos patienter under 65 år.
English: A total of 2,184 patients were treated; for both groups, patients were treated for at least 5 days and up to 22 days (mean 7 days).
Danish: I begge grupper blev patienterne behandlet i mindst 5 dage og højst 22 dage (7 dage i gennemsnit).
English: 7.5 mg once a day
Danish: 7,5 mg en gang daglig.
English: • Prevention of VTE - Fondaparinux is known to be mainly excreted by the kidney.
Danish: • Forebyggelse af VTE - Fondaparinux udskilles hovedsageligt via nyrerne.
English: Treatment of patients with acute symptomatic spontaneous superficial-vein thrombosis without concomitant Deep-Vein Thrombosis (DVT)
Danish: Behandling af patienter med akut, symptomatisk, spontan superficiel venetrombose, hvor patienten ikke samtidig har dyb venetrombose (DVT)
English: At the 10 mg dose used in the interaction studies, fondaparinux did not influence the bleeding time under acetylsalicylic acid or piroxicam treatment, nor the pharmacokinetics of digoxin at steady state.
Danish: Ved den i interaktionsstudier anvendte dosis på 10 mg påvirkede fondaparinux ikke blødningstiden under behandling med acetylsalicylsyre eller piroxicam og heller ikke digoxins farmakokinetik ved steady state.
English: • pain and swelling at injection site
Danish: • smerte og hævelse ved indstikstedet
English: Slide the sleeve up the body of the syringe until it locks into position over the needle.
Danish: Træk derefter hætten op over injektionssprøjten, indtil den låses over nålen.
English: The corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of DVT were 2.3% (13/559), 4.6% (17/368), 9.7% (14/145) and 11.1% (2/18) respectively, and in patients receiving the recommended regimen of unfractionated heparin in the treatment of PE were 6.9% (36/523), 3.1% (11/352), 11.1% (18/162) and 10.7% (3/28), respectively.
Danish: De tilsvarende incidenser hos patienter, der får den anbefalede behandling for DVT med enoxaparin var 2,3 % (13/559), 4,6 % (17/368), 9,7 % (14/145) henholdsvis 11,1 % (2/18), mens incidensen hos patienter, der fik den anbefalede behandling med ufraktioneret heparin mod PE var henholdsvis 6,9 % (36/523), 3,1 % (11/352), 11,1 % (18/162) og 10,7 % (3/28).
English: In a double-blind clinical study, 2,927 patients were randomised to receive fondaparinux 2.5mg once daily or dalteparin 5,000 IU once daily, with one 2,500 IU preoperative injection and a first 2,500 IU post-operative injection, for 7+2 days.
Danish: I et dobbeltblindt klinisk forsøg blev 2.927 patienter randomiseret til fondaparinux 2,5 mg en gang daglig eller dalteparin 5.000 IE en gang daglig, dog 2.500 IE præoperativt og 2.500 IE postoperativt første gang, i 7 + 2 dage.
English: These may affect more than 1 in 100 people treated with Arixtra.
Danish: Disse kan forekomme hos flere end 1 ud af 100 personer, som behandles med Arixtra.
English: • treat blood clots in blood vessels that are near the surface of the skin of the legs (superficialvein thrombosis).
Danish: at behandle blodpropper i blodkar nær hudoverfladen i benene (superficiel venetrombose).
English: Take special care with Arixtra:
Danish: Vær ekstra forsigtig med at tage Arixtra:
English: Rare: rash erythematous, pruritus
Danish: Sjælden: erythematøst hududslæt, pruritus
English: Fondaparinux should be used with care in these patients.
Danish: Fondaparinux bør anvendes med forsigtighed til disse patienter.
English: Since fondaparinux does not bind significantly to plasma proteins other than antithrombin, no interaction with other medicinal products by protein binding displacement are expected.
Danish: Da fondaparinux ikke bindes til andre plasmaproteiner end antitrombin, er der ingen forventning om interaktion med andre lægemidler i form af proteinbindingssubstitution.
English: A randomised, double blind, clinical trial (CALISTO) included 3002 patients with acute symptomatic isolated, spontaneous superficial-vein thrombosis of the lower limbs, at least 5 cm long, confirmed by compression ultrasonography.
Danish: Et randomiseret, dobbelblindt klinisk forsøg (CALISTO) inkluderede 3002 patienter med en mindst 5 cm lang, akut, symptomatisk, isoleret, spontan superficiel venetrombose i underekstremiteterne, der blev bekræftet ved kompressionsultralyd.
English: • Treatment of superficial-vein thrombosis - There are no clinical data available for the use of fondaparinux for the treatment of superficial-vein thrombosis in patients with body weight less than 50kg.
Danish: • Behandling af superficiel venetrombose - Der er ingen kliniske data for brug af fondaparinux til behandling af superficiel venetrombose hos patienter med en legemsvægt lavere end 50 kg.
English: Treatment should be initiated as soon as possible following diagnosis and after exclusion of concomitant DVT or superficial-vein thrombosis within 3 cm from the sapheno-femoral junction.
Danish: Behandlingen bør initieres hurtigst muligt efter diagnosticering og efter udelukkelse af samtidig dyb venetrombose (DVT) eller superficiel venetrombose inden for 3 cm fra den safeno-femorale overgang.
English: There are no data regarding the use of fondaparinux 2.5 mg in superficial-vein thrombosis patients with concomitant DVT or with superficial-vein thrombosis within 3 cm of the sapheno-femoral junction (see section 4.2 and 5.1).
Danish: Der er ingen data for brug af fondaparinux 2,5 mg til patienter med superficiel venetrombose med samtidig DVT eller med superficiel venetrombose inden for 3 cm fra den safeno-femorale overgang (se pkt.
English: In the Phase III UA/NSTEMI study, the most commonly reported non-bleeding adverse events (reported in at least 1% of subjects on fondaparinux) were headache, chest pain and atrial fibrillation.
Danish: I fase III-undersøgelsen for UA/NSTEMI var de hyppigst rapporterede bivirkninger udover blødning (der blev rapporteret hos mindst 1 % af alle patienter, som fik fondaparinux) hovedpine, brystsmerter og atrieflimren.
English: Fondaparinux is a synthetic and selective inhibitor of activated Factor X (Xa).
Danish: Fondaparinux er en fuld syntetisk og specifik Faktor Xa-hæmmer.
English: A total of 2,192 patients were treated; for both groups, patients were treated for at least 5 days and up to 26 days (mean 7 days).
Danish: I begge grupper blev patienterne behandlet i mindst 5 dage og højst 26 dage (7 dage i gennemsnit).
English: In subjects randomized to the “standard dose UFH” or the “low dose UFH” regimen the median dose of UFH was 85 U/kg and 50 U/kg, respectively.
Danish: Mediandosis af UFH var for patienter randomiseret til "standarddosis"-UFH-regimet og "lavdosis"-UFH-regimet henholdsvis 85 U/kg og 50 U/kg.
English: Clinically relevant non major bleeding occurred in 5 (0.3%) fondaparinux patients and 8 (0.5%) placebo patients.
Danish: Kliniske relevante, ikke-alvorlige blødninger opstod hos 5 (0,3) fondaparinuxpatienter og hos 8 (0,5 %) placebopatienter.
English: Syringe with a manual needle protection system Picture 2.
Danish: Injektionssprøjte med manuelt beskyttelsessystem af nålen Figur 2.
English: The initial dose should be given 6 hours following surgical closure provided that haemostasis has been established.
Danish: Startdosis bør gives 6 timer postoperativt, forudsat der er tilfredsstillende hæmostase.
English: In elderly healthy subjects, pharmacokinetics of fondaparinux is linear in the range of 2 to 8 mg by subcutaneous route.
Danish: Hos ældre raske forsøgspersoner, fandtes fondaparinux farmakokinetik lineær i området 2-8 mg ved subkutan indgift.
English: In this study, the incidence of total VTE was 4.6% (47/1,027) with fondaparinux, versus 6.1%: (62/1,021) with dalteparin: odds ratio reduction [95%CI] = -25.8% [-49.7%, 9.5%].
Danish: I dette studie var forekomsten af VTE i alt 4,6 % (47/1.027) med fondaparinux versus 6,1 % (62/1.021) med dalteparin: odds risikoreduktion -25,8 % [95 % CI, -49,7 % til 9,5 %].
English: Since fondaparinux does not bind significantly to plasma proteins other than ATIII, no interaction with other medicinal products by protein binding displacement are expected.
Danish: Da fondaparinux ikke bindes til andre plasmaproteiner end ATIII, er der ingen forventning om interaktion med andre lægemidler i form af proteinbindingssubstitution.
English: • For treatment of superficial-vein thrombosis- Fondaparinux should be used with caution in patients who are being treated concomitantly with other medicinal products that increase the risk of haemorrhage.
Danish: • Til behandling af superficiel venetrombose - Fondaparinux bør anvendes med forsigtighed til patienter, der er i samtidig behandling med andre præparater, der øger risikoen for blødning.
English: In patients undergoing surgery, timing of the first fondaparinux injection requires strict adherence in patients ≥75 years, and/or with body weight <50 kg and/or with renal impairment with creatinine clearance ranging between 20 to 50 ml/min.
Danish: Hos patienter, der gennemgår en operation, skal tidspunktet for første injektion af fondaparinux overholdes nøje hos de af patienterne, der er ≥75 år og/eller har en legemsvægt <50 kg og/eller med nedsat nyrefunktion med kreatininclearance i intervallet 20-50 ml/min.
English: Fondaparinux is known to be excreted mainly by the kidney.
Danish: Fondaparinux er kendt for hovedsagelig at blive udskilt via nyrerne.
English: Patients eligible for fondaparinux 2.5 mg treatment should have acute, symptomatic, isolated, spontaneous superficial-vein thrombosis of the lower limbs, at least 5 cm long and documented by ultrasonographic investigation or other objective methods.
Danish: Patienter, der er egnede til behandling med fondaparinux 2,5 mg, bør have en akut, symptomatisk, isoleret, spontan superficiel venetrombose i underekstremiteterne, der er mindst 5 cm lang, og som er dokumenteret ved ultralydsundersøgelse eller ved en anden objektiv metode.
English: No dosage reduction is required for patients with creatinine clearance > 20 ml/min.
Danish: Dosisreduktion er ikke påkrævet for patienter med kreatininclearance >20 ml/min.
English: In the pivotal UA/NSTEMI clinical trial, treatment with fondaparinux was restarted no earlier than 2 hours after sheath removal.
Danish: I det tilgrundliggende UA/NSTEMI-studie blev fondaparinuxbehandlingen ikke genoptaget før tidligst 2 timer efter fjernelsen af sheath.
English: LIST OF EXCIPIENTS Also contains: sodium chloride, water for injections, hydrochloric acid, sodium hydroxide.
Danish: Indeholder også: natriumchlorid, vand til injektionsvæsker, saltsyre, natriumhydroxid
English: Treatment should be continued until the risk of venous thrombo-embolism has diminished, usually until the patient is ambulant, at least 5 to 9 days after surgery.
Danish: Normalt vil det være, indtil patienten ikke længere er sengeliggende, dvs. mindst 5-9 dage efter operationen.
English: Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in adultsfor whom urgent (< 120 mins) invasive management (PCI) is not indicated (see sections 4.4 and 5.1).
Danish: Behandling af ustabil angina eller non-ST segment elevations myokardieinfarkt (UA/NSTEMI) hos voksne, hvor en omgående (<120 minutter) invasiv behandling (PCI) ikke er indiceret (se pkt.
English: There is no experience in the subgroup of patients with both high body weight (>100 kg) and moderate renal impairment (creatinine clearance 30-50 ml/min).
Danish: Der er ingen erfaringer med den undergruppe af patienter, som både har høj legemsvægt (>100 kg) og moderat nedsat nyrefunktion (kreatininclearance 30-50 ml/min).
English: Picture C
Danish: Figur C
English: 5 mg once a day
Danish: 5 mg en gang daglig.
English: The most commonly reported serious adverse reactions reported with fondaparinux are bleeding complications (various sites including rare cases of intracranial/ intracerebral and retroperitoneal bleedings).
Danish: De almindeligste alvorlige bivirkninger, der er rapporteret ved brug af fondaparinux, er blødningskomplikationer (forskellige steder, herunder sjældne tilfælde af intrakranielle/intracerebrale og retroperitoneale blødninger).
English: STEP BY STEP GUIDE TO USING ARIXTRA
Danish: VEJLEDNING I BRUG AF ARIXTRA (trin for trin) Instruktion
English: Therefore, fondaparinux is not recommended for the treatment of superficial-vein thrombosis in these patients (see section 4.2).
Danish: Derfor anbefales fondaparinux ikke til behandling af superficiel venetrombose hos disse patienter (se pkt.